| 11.13 0.03 (0.27%) | 07-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Verve Therapeutics, Inc. is a biotechnology firm dedicated to pioneering gene-editing treatments for individuals afflicted with cardiovascular diseases. Their flagship experimental therapy, VERVE-101, represents a singular gene-editing intervention engineered to irreversibly inactivate the PCSK9 gene within the liver. The company is also progressing with an ANGPTL3 program, which similarly aims to permanently switch off the ANGPTL3 gene in the liver. To support its endeavors, Verve maintains several key partnerships, including a collaboration and licensing pact with Beam Therapeutics Inc., a development and option agreement with Acuitas Therapeutics, Inc., and a Cas9 gene-editing technology license from The Broad Institute and the President and Fellows of Harvard College. Incorporated in 2018 and headquartered in Cambridge, Massachusetts, the organization operated under the name Endcadia, Inc. until its rebranding to Verve Therapeutics, Inc. in January 2019.
Mon, 28 Jul 2025
[Form 4] Verve Therapeutics, Inc. Insider Trading Activity - Stock Titan
Mon, 28 Jul 2025
Verve Therapeutics (VERV) Reported Results From its Heart-2 Phase 1b Trial for VERVE-102 - Yahoo Finance
Fri, 25 Jul 2025
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk - PR Newswire
Thu, 24 Jul 2025
VERV Stock Chart | VERVE THERAPEUTICS INC (NASDAQ:VERV) - ChartMill
Thu, 24 Jul 2025
Lilly and Verve announce expiration of Verve tender offer - PR Newswire
Thu, 10 Jul 2025
Verve Therapeutics, Inc. (VERV): A Bull Case Theory - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|